Metabolic analysis of early nonalcoholic fatty liver disease in humans using liquid chromatography-mass spectrometry

Autor:	Xiaochun Wang, Cheng Hu, Hui Lin, Qin Cao, Feng Mingli, Xiaoyu Zhuang, Jiaqi Zhang, Yuanye Jiang, Tao Wang, Qiaoli Sun
Jazyk:	angličtina
Rok vydání:	2021
Předmět:	0301 basic medicine medicine.medical_specialty Blood lipids Disease Gastroenterology General Biochemistry Genetics and Molecular Biology 03 medical and health sciences 0302 clinical medicine Metabolomics LC–MS/MS Internal medicine NAFLD Nonalcoholic fatty liver disease medicine Clinical significance Receiver operating characteristic business.industry Research General Medicine Gold standard (test) medicine.disease Early diagnosis 030104 developmental biology Medicine 030211 gastroenterology & hepatology Analysis of variance business Biomarkers
Zdroj:	Journal of Translational Medicine, Vol 19, Iss 1, Pp 1-10 (2021) Journal of Translational Medicine
ISSN:	1479-5876
Popis:	Background Nonalcoholic fatty liver disease (NAFLD) is a common metabolic disease that affects 20–30% of individuals worldwide. Liver puncture remains the gold standard for the diagnosis of liver diseases despite limitations regarding invasive nature and sample variability. It is of great clinical significance to find noninvasive biomarkers to detect and predict NAFLD. Objective The aims of this study were to identify potential serum markers in individuals with early-stage NAFLD and to advance the mechanistic understanding of this disease using a high-throughput mass spectrometry-based untargeted metabolomics approach. Methods One hundred and twelve patients with early-stage NAFLD aged 18–55 were recruited according to the guidelines. The control group included 112 healthy participants. The demographic, anthropometric, clinical and laboratory data of all participants were systematically collected. Serum samples were obtained after an overnight fast. The comprehensive serum metabolomic analysis was performed by ultra-performance liquid chromatography-Orbitrap mass spectrometry. The resultant data was processed by Compound Discover and SIMCA-P software to validate the potential biomarkers. Significantly altered metabolites were evaluated by variable importance in projection value (VIP > 1) and ANOVA (p Results The liver function test of early NAFLD patients showed no statistical differences to control group (p > 0.05). However, obvious differences in blood lipids were observed between subjects with NAFLD and controls (p 0.001). In total, 55 metabolites showed significant changes in experimental group were identified. The area under curve (AUC) values deduced by receiver operating curve (ROC) analysis indicated that these newly identified biomarkers have high predictability and reliability. Of these, 15 metabolites with AUC greater than 0.9 were of great diagnostic value in early NAFLD patients. Conclusion In this study, a total of 15 serum metabolites were found to strongly associate with early NAFLD. These biomarkers may have great clinical significance in the early diagnosis of NAFLD, as well as to follow response to therapeutic interventions.
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_dedup___::77778656ee90ac09baa557aa733f717a https://doaj.org/article/17c16735538a46d8ad7acae2b9393fda Zobrazit plný text záznamu Plný text ve formátu PDF Plný text ve formátu HTML
Nepřihlášeným uživatelům se plný text nezobrazuje	K zobrazení výsledku je třeba se přihlásit.